investors

Press Releases

DateTitle and SummaryView
November 14, 2014
Continued Positive Trends in Overall Survival and Progression-Free Survival;
Phase 3 Registration Program Anticipated to Start 1H15;
Company to Host Conference Call on Tuesday, November 18th
ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data at the Society for Neuro-Oncology Annual Meeting 2014
November 10, 2014
LOS ANGELES , Nov. 10, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") ( NYSE MKT : IMUC) today announced financial results for the quarter ended September 30, 2014 .  For the quarter ended September 30, 2014 , the Company incurred a net loss of $1.9 million or $0.03 per
ImmunoCellular Therapeutics Announces Third Quarter 2014 Financial Results
September 26, 2014
LOS ANGELES , Sept. 26, 2014 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") ( NYSE MKT : IMUC) today announced that Andrew Gengos , Chief Executive Officer, will present a corporate overview and business update at the Livingston Securities 7 th Annual Life Sciences
ImmunoCellular Therapeutics to Present at Livingston Securities Conference on October 1, 2014
September 24, 2014
Ex-Vivo Manipulation of Autologous Hematopoietic Stem Cells Complements Dendritic Cell-based Vaccine Platform; Potential to Develop Single-Agent and Combination Immunotherapeutics
ImmunoCellular Therapeutics Expands Cancer Immunotherapy Platform with Antigen-Specific T-cell Technology Licensed from Caltech
September 17, 2014
ICT-107 Phase II Update Selected for Oral Presentation at Society for Neuro-Oncology Meeting in November; ICT-121 and ICT-140 Programs on Track
ImmunoCellular Therapeutics Receives Positive Regulatory Feedback on ICT-107 Supporting Advancement to Registrational Phase III Testing in Newly Diagnosed Glioblastoma
August 7, 2014
Conference Call Today at 5:00 pm ET
ImmunoCellular Therapeutics Announces Second Quarter 2014 Financial Results
July 29, 2014
LOS ANGELES , July 29, 2014 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to report second quarter 2014 financial results on Thursday, August 7, 2014 . ImmunoCellular will host a conference call and webcast to discuss its
ImmunoCellular Therapeutics to Report Financial Results for the Second Quarter 2014 on August 7, 2014
June 1, 2014
Pre-specified MGMT and HLA Subgroup Analyses Show Potentially Clinically Meaningful Survival Advantages for ICT-107 Treated Patients
Previously Reported Total Population Overall Survival and Progression-Free Survival Rates Sustained
Data Support Rationale for Phase III; US and EU Regulatory Meetings to Discuss Registration Strategy Planned for 3Q14
ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data in Patients with Newly Diagnosed Glioblastoma at the 2014 ASCO Annual Meeting
May 8, 2014
Conference Call Today at 5:00 pm ET
ImmunoCellular Therapeutics Announces First Quarter 2014 Financial Results
May 1, 2014
LOS ANGELES , May 1, 2014 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to report first quarter 2014 financial results on Thursday, May 8, 2014 . ImmunoCellular will host a conference call and webcast to discuss its financial
ImmunoCellular Therapeutics to Report Financial Results for the First Quarter 2014 on May 8, 2014
Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved